Regulated information

Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT

Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. 

Q3 2017 sales of €88.3 million, up 5.2% at constant exchange rates

For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates.

Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million

At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2017 

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2016 (french version)

The registration document of Vetoquinol relative to fiscal year 2016, including the annual financial report relative to fiscal year 2016, was filed with the Autorité des marchés financiers ("the AMF") on April 26, 2017.

Q1 2017 sales stable at €86.1 million

Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like. 

All key financial indicators up in 2016

At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. 

2016 sales: €350.3 million 4.3% like-for-like growth

The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.

Vétoquinol announces opening of its first decentralized R&D center in Canada

Vétoquinol to market and distribute Vetprofen in the United States

3rd quarter revenues confirm promise of
strong growth prospects for 2007

For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the
corresponding period in 2006.

Reports very good first half, confirming that 2007 performance is set to surpass targets

Presentation of Vétoquinol’s results for the first half of 2007

2007 Half year results

Rapport semestriel 2007 « narratif » (french)

Suite à la publication du 26 juillet dernier, Vétoquinol a réalisé au 1er semestre 2007 un
chiffre d’affaires de 111,1 M€ contre 98,4 M€ au cours de la même période de l’exercice
précédent, soit une progression de 12,9 %.
A cours de change et périmètre constants, la progression est de 10,1 %.

Business is strong in first-half of 2007 : + 12.9%

2007 Half year Financial Report

Vétoquinol creates a subsidiary in Portugal

2006 Financial Report

Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent.
Le résultat opérationnel courant, qui s’élève à 25,6 M€, est en augmentation de 10,8%.
Enfin, le résultat net de 15,8 M€ progresse de 27,2% et représente 7,5% du chiffre d’affaires.
Cette croissance a été maîtrisée et équilibrée.

Activity Report 2006

Annual earnings for 2006: a year of good performance

Présentation des résultats 2006 de Vétoquinol (french)

Vétoquinol reports one of its industry’ strongest growth performances in 2006

Sustained revenue growth in 2006

Vétoquinol strengthens its position in the United States